What You Need to Know About Clinical Trials

What You Need to Know About Clinical Trials

While the OI community and the entire world eagerly await a coronavirus vaccine, we want to briefly explain the importance of clinical trials and how people with OI can get involved in helping expand medical knowledge.

CLICK HERE to view the OI Foundation’s What you Need to Know About Clinical Trials fact sheet

OIF Young Investigators Symposium: Call for Abstracts!

OIF Young Investigators Symposium
Basic, Translational and Clinical Aspects of Osteogenesis Imperfecta and Other Rare Bone Disorders

The Osteogenesis Imperfecta Foundation (OIF) is seeking abstract submissions from young investigators working in the field of osteogenesis imperfecta (OI) and/or rare bone disease research to be presented at the 2020 OIF Young Investigator Symposium on Tuesday, November 17 from 5pm-8pm EST.

This virtual one-day meeting is being offered as a pre-meeting event for the 2020 International Conference on Children’s Bone Health’s Virtual Forum and is open to US and international participants. Investigators are welcome to submit abstracts to both meetings. Submissions for the Young Investigator Symposium will be reviewed by a scientific review committee and selected abstracts will be invited to present a 10-15 minute overview of their work with 5 minutes for questions from the audience. Investigators are encouraged to share novel findings.
For more information about the ICCBH Virtual Forum visit www.iccbh.org.

Date of Meeting: November 17, 2020 from 5pm-8pm EST

Deadline for Submission: October 1, 2020

To Apply: Click here for Abstract Submission Form or contact Erika Carter at ecarter@oif.org

To Attend: Click here to register to attend. Registration to attend the meeting is free of charge.



  • Must be a medical or graduate student
    • OR post-doctoral fellow
    • OR young faculty within 10 years of last graduate degree
  • Areas of research include, but are not limited to: Osteogenesis imperfecta, Paget’s disease of bone, Generalized Arterial Calcification of Infancy (GACI), Hypophosphatemia, Autosomal Recessive Hypophosphatemic Rickets (ARHR2), Osteopetrosis, Fibrodysplasia Ossificans Progressiva (FOP), Fibrous Dysplasia and McCune Albright Syndrome, Hypophosphatasia (HPP), Gorham-Stout Disease, Melorheostosis, Jansen’s disease, X-Linked Hypophosphatemia (XLH), Multiple Hereditary Exostoses (MHE), and Multicentric Carpotarsal Osteolysis Syndrome (MCTO)

The OI Foundation is committed to supporting research to help improve the quality of life for people living with OI. This often times includes engaging groups throughout the rare bone disease community, such as the Rare Bone Disease Alliance (www.rbdalliance.org). The OI Foundation is pleased to open this meeting to the entire rare bone disease research community.

Thank you, PanAmerican Seed!

Thank you, PanAmerican Seed! 
Last year, the plant breeders and researchers at PanAmerican Seed launched a selection of impatiens that displayed high resistance to Impatiens downy mildew – Beacon Impatiens. In the spirit of bringing light — and happiness! — to gardens everywhere, they pledged to donate 3% of sales during the 2020 season to the OI Foundation.

Last week, PanAmerican Seed presented a $55,943 donation to past OIF Board Member Tony Benish on behalf of the OI Foundation! Thank you so much for supporting the mission of the OI Foundation! Click here to learn more about PanAmerican Seed’s Beacon Impatiens.


Survey Opportunity: Help Orthopedic Surgeons Learn About OI

The OI Foundation would like to bring your attention to a new survey to help orthopedic surgeons learn more about OI.

A group of orthopedic surgeons with extensive experience in treating OI have come together to learn more about the patient experience. Your participation will help these OI experts better understand the needs of people living with osteogenesis imperfecta.

Please take 5-10 minutes to complete the survey at https://www.surveymonkey.com/r/J9653VK.

This survey will be available until Sunday, October 18, 2020.